Stock STAB STATERA BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Statera Biopharma, Inc. Nasdaq

Equities

STAB

US8575611046

Delayed Nasdaq
Other stock markets
 12:02:56 2024-04-16 pm EDT 		5-day change 1st Jan Change
0.0006 USD 0.00% Intraday chart for Statera Biopharma, Inc. 0.00% -99.98%
2023 Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs. CI
2023 Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs.
CI
STATERA BIOPHARMA, INC. : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
AQ
STATERA BIOPHARMA, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K)
AQ
Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index
CI
Statera Biopharma, Inc.(OTCPK:STAB) dropped from NASDAQ Composite Index
CI
STATERA BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
AQ
STATERA BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Statera Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Statera Biopharma : Material Agreement - Form 8-K
PU
STATERA BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
AQ
Statera Biopharma, Inc. announced that it has received $0.4 million in funding from Silverback Capital Corporation
CI
Statera Biopharma, Inc. announced that it expects to receive $0.765 million in funding
CI
STATERA BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Statera Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
STATERA BIOPHARMA, INC. : Other Events (form 8-K)
AQ
STATERA BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
STATERA BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Statera Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
US Futures Lower Amid Earnings Reports, Ahead of Flash PMI Data
MT
Top Premarket Gainers
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. STAB Stock
  4. STAB Stock
  5. News Statera Biopharma, Inc.